Blog
    Regulatory UpdateFor PhysiciansJuly 3, 2026

    FDA peptide bulk substance and safety signals update

    Review FDA Category 2 classifications for BPC-157 and CJC-1295 alongside emerging safety signals for Semaglutide, including NAION and pulmonary aspiration risk.

    This content is sourced exclusively from TruthTides clinical reference data and does not constitute medical advice.

    1. Clinical Question

    How holds the current regulatory landscape for compounded peptide bulk substances, and what emerging safety signals have been identified for FDA-approved and investigational peptide therapies?

    2. Evidence Snapshot

    • Regulatory Statuses: 10 peptides evaluated against FDA 503A and 503B bulk substance lists as of March 2026.
    • Safety Signals (FAERS): Comprehensive signal detection for Semaglutide including 187,757 GLP-1 RA reports through 2023.
    • Clinical Trials: Phase II and III data for Semaglutide (STEP 1, SELECT), Tirzepatide (SURMOUNT-1, SURMOUNT-5), Retatrutide (TRIUMPH-3), and Thymosin Alpha-1.
    • Regulatory Outcomes: Multiple peptides moved to Category 2 (significant safety risk) or withdrawn from nomination lists.

    3. What the Research Shows

    Evidence regarding the regulatory and safety profile of several high-profile peptides indicates significant shifts in compounding eligibility and emerging postmarketing safety signals.

    Regulatory Classifications for Bulk Substances As of March 2026, the FDA has identified several peptides as Category 2 bulk substances under Section 503A, designating them as having significant safety risks and rendering them ineligible for routine compounding. BPC-157 was classified as Category 2 in September 2023, citing immunogenicity concerns and a lack of safety data. Similarly, TB-500 is classified under Category 2 due to immunogenicity risks and an absence of human exposure data. GHK-Cu is also listed in Category 2 for 503A and 503B due to immunogenicity risk.

    Several peptides previously nominated for compounding have seen their nominations withdrawn or their statuses updated. Ipamorelin, Selank, and AOD-9604 had their nominations withdrawn in September 2024. CJC-1295 was removed after nomination withdrawal, with the FDA citing safety issues such as increased heart rate. Thymosin Alpha-1, which is approved in over 35 countries as Zadaxin but not FDA-approved, was moved from Category 2 in September 2023 to being removed pending advisory review in September 2024, yet it remains a substance of concern under interim policy.

    Postmarketing Safety Signals (FAERS) For FDA-approved GLP-1 receptor agonists like Semaglutide, clinical data and FAERS reports have identified several gastrointestinal and systemic safety signals. Strong, elevated Relative Reporting Ratio (ROR) signals exist for nausea, vomiting, and delayed gastric emptying. The FDA Ozempic label was updated in 2025 to include pulmonary aspiration risk during general anesthesia, contributed to by delayed gastric emptying.

    Emerging signals for Semaglutide include intestinal obstruction (ileus), which was added to the label postmarketing, and nonarteritic anterior ischemic optic neuropathy (NAION), with 96 cases reported through December 2024. NAION is currently under EMA review as of January 2025. While suicidal ideation is under evaluation and listed in Section 5.9 of the label, current data does not support a higher risk compared to background rates.

    Clinical Trial Outcomes In Phase III obesity trials, Tirzepatide (SURMOUNT-1) demonstrated a 22.5% weight loss, which was superior to Semaglutide in the SURMOUNT-5 trial. Retatrutide (Phase II) showed 24.2% weight loss at a 12mg dose. In contrast, Thymosin Alpha-1 failed to show a mortality reduction in its Phase III trial for sepsis (NCT02867267).

    4. Mechanism

    Mechanistic data for these peptides is limited within the provided records. For Semaglutide, the delayed gastric emptying mechanism is noted as a contributor to risks of pulmonary aspiration and potential impacts on the absorption of oral medications. FDA citations for CJC-1295 safety signals include the peptide's impact on increasing heart rate.

    5. Limitations of the Evidence

    The primary limitation for several peptides, particularly BPC-157 and TB-500, is a total lack of human safety and exposure data in the clinical record. For emerging signals such as NAION and suicidal ideation associated with Semaglutide, the evidence is currently under evaluation or formal review (EMA), meaning definitive causality remains unestablished in the provided data. Many peptides discussed, such as Selank and Semax, are approved in international jurisdictions (Russia) but lack FDA evaluation for safety and efficacy.

    6. Clinical Takeaway

    Regulatory authorities have significantly restricted the compounding of many peptides—including BPC-157, CJC-1295, and Ipamorelin—by classifying them as Category 2 bulk substances due to safety concerns like immunogenicity and cardiovascular effects. While Semaglutide and Tirzepatide demonstrate high efficacy in Phase III trials, clinical monitoring for emerging signals such as NAION, ileus, and pulmonary aspiration is increasingly emphasized in updated labeling and regulatory reviews.

    7. Sources

    • FDA Regulatory Status Records (March 2026 Update)
    • FAERS Safety Signal Database (Records: 502f8ab5, be753983, 60c7beaa)
    • Clinical Trial Records (NCT03548935, NCT04184622, NCT04881706, NCT02867267)
    • FDA Warning Letters: Tailor Made Compounding (2020), Predator Nutrition (2020)

    Referenced Peptides

    bpc 157semaglutidetirzepatidethymosin alpha 1cjc 1295

    This content was generated from TruthTides clinical reference data. It does not constitute medical advice. Always consult a qualified healthcare provider.